Last updated on July 2020

Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children Adolescents and Adults 2 to 55 Years of Age


Brief description of study

Primary Objective:

To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW conjugate vaccine compared with those observed following the administration of a single dose of Menactra

Secondary Objective:

Immunogenicity: To describe the antibody responses to the meningococcal serogroups A, C, Y, and W before and 30 days (+14 days) after vaccination with MenACYW conjugate vaccine or Menactra.

Safety: To describe the safety profile of MenACYW conjugate vaccine and that of Menactra.

Detailed Study Description

The duration of each participant's participation in the study will be approximately 30 to 44 days

Clinical Study Identifier: NCT04368429

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.